An Efficient Synthesis of a 1,3-Dioxolan-4-one-Based Impurity of Allisartan Isoproxil
Pharmaceutical Fronts · 01.09.2026 · 08 (03) · e230-e238
DOI: 10.1055/a-2929-2068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Fronts, erschienen am 01.09.2026. Verfasst von Zhihao Du und 4 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypertension is closely associated with aberrant activation of the renin–angiotensin system. Allisartan isoproxil, a prodrug angiotensin II receptor blocker, exhibits improved pharmacokinetic stability and medication safety compared with agents that rely on CYP450-mediated metabolism. However, multiple process-related impurities are inevitably generated during the industrial synthesis of allisartan isoproxil. Among its impurity profile, Impurity V is particularly noteworthy because of its unique 1,3-dioxolan-4-one structure. As a typical process-related impurity, it cannot be readily accessed through simple chemical transformations. The aim of this study is to establish an efficient synthetic route to Impurity V for the first time. Starting from N-benzylimidazole, we designed and developed a novel 13-step synthetic route to the target product. A key intramolecular cyclization catalyzed by I2 under mild conditions enabled the efficient construction of the imidazo-fused 1,3-dioxolane lactone core in 57% yield while effectively suppressing the undesired decarboxylation side reaction. Furthermore, optimization of the C5 chlorination step using a dimethyl sulfoxide/NaHCO3/CHCl3 system significantly improved the yield from 36 to 81%. Impurity V was subsequently obtained through sequential multistep oxidation, alkylation, and deprotection reactions. This route enabled the 10-g scale preparation of Impurity V with an overall yield of 3.6%. This work provides a practical synthetic route to an unstable lactone system and delivers a reliable reference standard for analytical method development, thereby supporting quality control and regulatory submission of allisartan isoproxil.
Zitieren
APA
Du, Z., Gao, X., Zhang, T., Chen, D., & Liu, Y. (2026). An Efficient Synthesis of a 1,3-Dioxolan-4-one-Based Impurity of Allisartan Isoproxil. Pharmaceutical Fronts, 08(03), e230-e238. https://doi.org/10.1055/a-2929-2068
Vancouver
Du Z, Gao X, Zhang T, Chen D, Liu Y. An Efficient Synthesis of a 1,3-Dioxolan-4-one-Based Impurity of Allisartan Isoproxil. Pharmaceutical Fronts. 2026;08(03):e230-e238. doi:10.1055/a-2929-2068
BibTeX
@article{Du2026,
author = {Du, Zhihao and Gao, Xin and Zhang, Tengyu and Chen, Dongsheng and Liu, Yu},
title = {An Efficient Synthesis of a 1,3-Dioxolan-4-one-Based Impurity of Allisartan Isoproxil},
journal = {Pharmaceutical Fronts},
year = {2026},
volume = {08},
number = {03},
pages = {e230--e238},
doi = {10.1055/a-2929-2068}
}
EUVIMED